Kairos Pharma Ltd (KAPA) Annual Balance Sheets

Annual · GAAP · USD millions
Access KAPA quarterly Balance Sheets →
Changes in quarterly balance sheet trends offer perspective on how Kairos Pharma Ltd balances growth, leverage, and shareholder equity.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2025)
(Dec 31 2024)
Assets
Cash & cash equivalent4.49
Cash & Short-term Investments4.00
Other Current Assets0.85
Prepaid Expense And Other Assets Current0.05
Total Current Assets5.39
Intangible Assets0.06
Deferred Costs, Noncurrent AS1.09
Vendor Advances Net0.85
Total Assets6.54
Liabilities
Accounts Payable and Accrued Liabilities, Current LI0.20
Total Current Liabilities0.20
Total Long-term Debt0.00
Total Liabilities0.20
Stockholders' Equity
Common Stock Value0.02
Additional Paid In Capital Common Stock20.58
Retained Earnings / Accumulated Deficit-14.26
Other Equity0.00
Common Stockholder's Equity6.34
Total Stockholder's Equity6.34
Liabilities & Stockholder's Equity6.54
4 historic quarters locked

Sign in to unlock the full Kairos Pharma Ltd balance sheet history.

About Kairos Pharma Ltd Annual Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-K filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: March 31, 2026
  • Source: form10-k.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001493152-26-014159

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API License